Adverum Biotechnologies receives fast track designation for wet AMD therapy

The FDA granted fast track designation for ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.
ADVM-022 utilizes a proprietary vector capsid carrying an aflibercept coding sequence under the control of a proprietary expression cassette, the release said. The treatment is administered as a single intravitreal injection.
An open-label, multicenter phase 1 dose-escalation trial will assess the safety and tolerability of ADVM-022 in patients with wet AMD who are responsive to anti-VEGF

Full Story →